{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:13:53Z","timestamp":1781093633559,"version":"3.54.1"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101ra) na\u00efve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network. Change from baseline was evaluated in glycated haemoglobin (HbA1c), body weight, blood lipids, and blood pressure over 12\u2009months of follow\u2010up. Outcomes were analysed in patients with at least a baseline and \u22651 follow\u2010up measurement, using mixed\u2010effect models for repeated measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 932 T2D patients initiating oral semaglutide identified, 731 were GLP\u20101ra na\u00efve (mean [standard deviation] age, 62 [11] years; baseline HbA1c, 70 [14] mmol\/mol; baseline body weight, 102 [19] kg). In 320 patients with an average follow\u2010up of 8.1\u2009months the mean (95% confidence interval) change in HbA1c from baseline was \u221216.05 (\u221212.57, \u221219.54) mmol\/mol at 12\u2009months, of whom 70% achieved personalized HbA1c targets. Body weight was reduced by \u22124.73 (\u22123.63, \u22125.83) kg at 12\u2009months in 260 patients over an average of 8.2\u2009months follow\u2010up. Minimal changes were observed in blood lipid parameters and diastolic blood pressure, with moderate changes in systolic blood pressure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among Dutch T2D patients who were GLP\u20101ra na\u00efve and initiated oral semaglutide, significant reductions in HbA1c and body weight were observed over 12\u2009months, consistent with prospective clinical trial data. These results provide a first\u2010look insight into real\u2010world glycaemic control and body weight reduction in early adopters of oral semaglutide in the Netherlands.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70251","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:32:46Z","timestamp":1763368366000},"page":"895-905","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2010world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the\n                    <scp>PHARMO<\/scp>\n                    data network"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4897-827X","authenticated-orcid":false,"given":"Abigail","family":"Postema","sequence":"first","affiliation":[{"name":"The PHARMO Institute  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordy","family":"Gaspersz","sequence":"additional","affiliation":[{"name":"The PHARMO Institute  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda N.","family":"Baak","sequence":"additional","affiliation":[{"name":"The PHARMO Institute  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline L.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Novo Nordisk  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hoogstraten","sequence":"additional","affiliation":[{"name":"Novo Nordisk  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Meinicke","family":"Hagelund","sequence":"additional","affiliation":[{"name":"Novo Nordisk  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernie J. A.","family":"Penning\u2010van Beest","sequence":"additional","affiliation":[{"name":"The PHARMO Institute  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jetty A.","family":"Overbeek","sequence":"additional","affiliation":[{"name":"The PHARMO Institute  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"e_1_2_9_3_1","unstructured":"International Diabetes Federation.Diabetes Facts and Figures.2025https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/"},{"key":"e_1_2_9_4_1","unstructured":"VZinfo.Diabetes mellitus.2025https:\/\/www.vzinfo.nl\/diabetes-mellitus"},{"key":"e_1_2_9_5_1","unstructured":"International Diabetes Federation.IDF global clinical practice recommendations for managing type 2 diabetes: 2025.https:\/\/idf.org\/t2d-cpr-2025"},{"issue":"165","key":"e_1_2_9_6_1","article-title":"Belangrijke wijziging van behandelrichtlijn \u2018Diabetes mellitus type 2","volume":"2021","author":"Sern\u00e9 EH","year":"2021","journal-title":"Richtlijnen"},{"key":"e_1_2_9_7_1","unstructured":"European Medicines Agency.Summary of product characteristics: Ozempic.2025https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf"},{"key":"e_1_2_9_8_1","unstructured":"European Medicines Agency.Summary of product characteristics: Rybelsus\u2014semaglutide.2025https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rybelsus"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0883"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30192-5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30194-9"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30075-9"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06142-3"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01588-5"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01614-6"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01525-y"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01719-6"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14219"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15493"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30074-7"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S247575"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S381728"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14453"},{"key":"e_1_2_9_30_1","unstructured":"Diabetes Fond.HbA1c\u2010omrekentabel.2025https:\/\/www.diabetesfonds.nl\/uploads\/2024-11\/hba1c-omrekentabel.pdf"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01590-x"},{"key":"e_1_2_9_32_1","unstructured":"Diabetesvereninging Nederland.New guideline for the treatment of type 2 diabetes.2025https:\/\/www.dvn.nl\/nieuws\/nieuwe-richtlijn-behandeling-diabetes-type-2"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14291"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S389598"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70251","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70251","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:48:22Z","timestamp":1769719702000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/dom.70251"],"URL":"https:\/\/doi.org\/10.1111\/dom.70251","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70251\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70251\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70251\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70251\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70251\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70251\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70251\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"2025-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}